Zenapax Smart humanized Anti-Tac antibody targeted at the interleukin-2 receptor on activated T cells: Partner Hoffmann-La Roche began a Phase III trial in 250

Protein Design Labs Inc. (PDLI), Mountain View, Calif.

Read the full 88 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE